BRCA2 and breast cancer: Breast cancer is the second-leading cause of cancer-related death for women in the United States.1 It is estimated that 10% of these breast cancer diagnoses are attributed to pathogenic variants.2 More than 50% of these pathogenic variants are secondary to high penetrance genes, such as BRCA1 and BRCA2, which confer a 50–85% lifetime likelihood of developing breast cancer.2,3 Knowledge of this risk is imperative, because it alters surveillance, surgical interventions, and therapeutic recommendations for patients and their families.